Souhaitez-vous accéder aux communiqués récents ?

Oslo, Norway, 6 November 2014: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for third...

Phase 2b results demonstrate significant and sustained efficacy in treating human papilloma virus and precancerous lesions of the cervix Oslo, Norway, 4 November 2014:  Photocure ASA (OSE: PHO), a...

Photocure will present its third quarter report on Thursday 6 November 2014 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET) and representatives from the company will...

Cysview® improves detection of Non-Muscle Invasive Bladder Cancer (NMIBC) beyond that achieved with current standard of care Oslo, Norway, 23 September 2014:  Photocure ASA (OSE: PHO), a specialty...

Oslo, Norway, 26 August 2014: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for second...

Oslo, Norway, 18 August 2014: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces today that Photocure and Salix...

Photocure will present its second quarter report on Tuesday 26 August 2014 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET) and representatives from the company will...

Oslo, Norway, 10th July 2014:  Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, is pleased to note that updated expert...

Bill makes most up-to-date cancer treatment available to patients; requires fair payment policy for hospitals Oslo, Norway, 25 June 2013:  Photocure ASA (OSE: PHO), a specialty pharmaceutical...

Oslo, Norway, 27 May, 2014. The Annual General Meeting in Photocure ASA took place on 27 May, 2014. A new Board of Directors was elected and consists of the following members until next Annual...